CNBC's Seema Mody reports Pfizer and Johnson & Johnson are scrapping their phase three studies of Alzheimer's drug known as "Bapi" after it failed to slow memory loss.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT